Plain-English translation of NCT05495906 on ClinicalTrials.gov ↗ · Source last updated · Translation generated ·
Phase 4 — The treatment has already been approved. Researchers are tracking how it works in a large number of people over time.
This trial is testing the (a vaccine that protects against nine strains of the human papillomavirus) in women living with HIV. Researchers want to find out whether women in this group need two or three doses of the vaccine to build protection against HPV and the cervical cancer it can cause. You'll be randomly assigned to receive either the standard three-dose schedule or a two-dose schedule with doses spread over a longer period.
Women living with HIV are at much higher risk of developing HPV-related cervical cancer, but there's very little information about how well this nine-strain vaccine works in this population. By testing whether fewer doses might work just as well, researchers hope to make it easier and more affordable to vaccinate millions of women with HIV around the world and help eliminate cervical cancer.
You likely qualify if…
You likely don't qualify if…
You will receive vaccine injections on a set schedule over up to 12 months, then be followed for two years total. If you're in the standard group, you'll get three doses at 0, 2, and 6 months; if you're in the extended group, you'll get doses at 0 and 6 months, with a third dose at 12 months. The study team will check your immune response to the vaccine through blood tests and monitor you for any side effects during your visits.
AI-generated summary from trial data · Jun 9, 2026 · Not medical advice
Canada